Skip to main content

THEON Announces Results of the Rights Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION. This announcement is not a prospectus and does not constitute an offer to sell or the solicitation of an offer to purchase the securities described herein, nor shall there be any sale of the securities referred to herein in or into any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Neither this communication nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction....

Continue reading

VALUE LINE, INC. ANNOUNCES EARNINGS

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Value Line, Inc., (NASDAQ: VALU) reported financial results for the first half of its fiscal year, ended October 31, 2025.During the six months ended October 31, 2025, the Company’s net income of $12,142,000, or $1.29 per share, was 4.9% above net income of $11,572,000, or $1.23 per share, for the six months ended October 31, 2024.   The Company’s revenues of $10,275,000 from Eulav Asset Management (EAM) increased $1,404,000 or 15.8% above the prior fiscal year.   During the six months ended October 31, 2025, the Company’s total investment gains of $3,201,000 was 10.6% above total investment gains in the prior fiscal year.   Retained earnings at October 31, 2025, were $119,426,000, an increase of 5.3% compared to retained earnings at April 30, 2025.   Shareholders’ equity reached $105,489,000...

Continue reading

EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results

VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today reported the Company’s consolidated interim financial results for the fourth quarter and fiscal year ended September 30, 2025. All values in thousands and denoted in CAD unless otherwise stated.Reported revenue for Q4 2025 of $6,219, an increase of $2,585 relative to the comparable period in the prior year. During the period, the company commissioned one large-scale and six small-scale machines, sold a refurbished 120kW machine, and continued the fabrication of two large-scale machines on contract. Reported Adjusted EBITDA(1) income for Q4 2025 of $1,407, an increase of $957 from the comparable period in the prior year, with the increase driven by machine sales and the production...

Continue reading

BRMG, a Hover Group Company, Ends 2025 with Strong Foundation and Expanding Operator Pipeline Ahead of 2026 Scale-Up

BRMG, a Hover Group company, today announced its Q4 and fiscal year-end results, closing FY2025 with a strengthened operating foundation, accelerated growth, and clear momentum heading into FY26. TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) — The company delivered significant year-over-year revenue growth, representing a 133% increase from FY2024. This surge reflects the strong market adoption of BRMG’s Operator-first model, which continues to attract senior practitioners seeking independence, alignment, and a modern alternative to traditional agency structures. Throughout the year, BRMG Operators also surpassed a key performance milestone: each Operating Partner achieved an annual portfolio value above all targets, demonstrating both the maturity of the model and the strength of client demand across the network. BRMG ended FY2025 performing...

Continue reading

Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2025 Financial Results

CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2025 and are reported in U.S. Dollars under GAAP. Financial Highlights:Revenue for Q4 2025 was $68.3 million compared to $61.3 million for Q4 2024, representing an 11% increase. Sequential organic revenue growth from Q3 2025 was strong at 5%. Recurring Revenue1 for Q4 2025 was strong at 80% of total revenue, driven by the growth in the Company’s resupply platform. Adjusted EBITDA1 for Q4 2025 was $14.9 million (21.8% as a percentage of revenues) compared to $13.4...

Continue reading

Ocean Power Technologies, Inc. Announces Second Quarter Fiscal 2026 Results

Year Over Year Backlog increases to $15.0 Million as Commercial Momentum Accelerates MONROE TOWNSHIP, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), today announced financial results for its fiscal second quarter (“2Q26”) ended October 31, 2025. Highlights include: 2Q26 RESULTS and RECENT HIGHLIGHTSBacklog at October 31, 2025 was approximately $15.0 million, an increase of $11.2 million and nearly 300% over the prior year period. Pipeline as of October 31, 2025 stands at $137.5 million, an increase of $53.1million and 63% increase over the $84.4 million pipeline at October 31, 2024. During the quarter, OPT shipped eight WAM-V® autonomous surface vehicles, marking a strategically meaningful milestone for the Company. The shipments highlight...

Continue reading

Grande Group Limited Announces Financial Results for the First Half of Fiscal Year 2026

Hong Kong, Dec. 12, 2025 (GLOBE NEWSWIRE) — GRANDE GROUP LIMITED (“GRAN” or the “Company”) (Nasdaq: GRAN), a Hong Kong-based financial services provider which principally engages in the provision of corporate finance advisory services and IPO sponsor services through its Hong Kong subsidiary, Grande Capital Limited, today announced its unaudited financial results for the six months ended September 30, 2025 (“First Half 2026”). First Half of Fiscal Year 2026 Financial Results    For the Six Months Ended September 30,  Selected Unaudited Interim Condensed Consolidated Statements of Income Data   2025USD     2024USD     Change%  Revenue     293,929       1,750,043       (83.2 )Cost of revenue     336,543       499,092       (32.6 )General and administrative expenses     1,158,751       716,183       61.8  Unrealized...

Continue reading

AMREP Reports Second Quarter Fiscal 2026 Results

HAVERTOWN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $1,200,000, or $0.22 per diluted share, for its 2026 fiscal second quarter ended October 31, 2025 compared to net income of $4,042,000, or $0.75 per diluted share, for the same period of the prior year. For the first six months of 2026, AMREP had net income of $5,892,000, or $1.09 per diluted share, compared to net income of $8,106,000, or $1.51 per diluted share, for the same period of 2025. Revenues were $9,398,000 and $27,250,000 for the second quarter and first six months of 2026 and $11,906,000 and $30,997,000 for the second quarter and first six months of 2025. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with...

Continue reading

Edesa Biotech Reports Fiscal Year 2025 Results

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates that recruitment will begin by midyear 2026, subject to the completion of clinical-grade drug manufacturing and regulatory approvals. In its respiratory program, Edesa reported that a Phase 3 study of its monoclonal antibody, paridiprubart (EB05), met primary and secondary endpoints...

Continue reading

Rent the Runway, Inc. Announces Third Quarter 2025 Results

Continued Growth of the Business with Q3 Ending Active Subscribers +12.4% YoY; Revenue up 15.4% YOY Closed Transformative Recapitalization Plan, Strengthening the Balance Sheet and Injecting Capital into the Business Expanded our Community-driven Organic Growth Strategy to Drive Brand Awareness and Acquisition NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Rent the Runway, Inc. (“Rent the Runway” or “RTR”) (NASDAQ: RENT), the company transforming the way women get dressed, today reported financial results for the fiscal quarter ended October 31, 2025. Rent the Runway is delivering on its multi-year transformation plan, achieving substantial growth on the heels of its largest inventory investment in company history. Our strategic repositioning achieved a milestone in October 2025 with the close of the transformative recapitalization...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.